PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers

Manuscript Number: 

17-0129R1

Author(s): 
Azadeh Firouzian, Roger N. Gunn, Robert Howard, Ivan Koychev, Jennifer Lawson, Simon Lovestone, Clare MacKay, Basil Ridha, Lynn Rochester, James B. Rowe, Barbara J. Sahakian, Alan Thomas, Giovanna Zamboni, Henrik Zetterberg, Dominic ffytche

Disclosures

Dominic ffytche

  • Nothing to Disclose

Azadeh Firouzian

  • Nothing to Disclose

Roger N. Gunn

  • Consulting Fees:
    Consultant for Abbvie, Biogen and Cerveau

Robert Howard

  • Nothing to Disclose

Ivan Koychev

  • Nothing to Disclose

Jennifer Lawson

  • Nothing to Disclose

Simon Lovestone

  • Consulting Fees:
    SomaLogic medical advisory board (unpaid) Consultancy to OptumLabs, Eisai, J&J
    Lecture Fees:
    Eisai (to be claimed)
    Patents/Royalties
    Named as senior inventor on patents on biomarkers held by KCL and Proteome Sciences
    Grants
    • Agency: 
      AstraZeneca
      Dates: 
      2014-2019
    • Agency: 
      EFPIA companies via IMI
      Dates: 
      2012-2020

Clare MacKay

  • Nothing to Disclose

Basil Ridha

  • Nothing to Disclose

Lynn Rochester

  • Nothing to Disclose

James B. Rowe

  • Consulting Fees:
    Advisory board membership for Medical Research Council, Wellcome Trust and National Institute for Health Research; Consultancy for Asceneuron;
    Grants
    • Agency: 
      AZ Medimmune
      Dates: 
      2015-6
    • Agency: 
      Janssen
      Dates: 
      2017-20

Barbara J. Sahakian

  • Consulting Fees:
    Cambridge Cognition, PEAK, Mundipharma, Latium
    Equity:
    Cambridge Cognition Stock Options
    Patents/Royalties
    Royalties for CANTAB, Cambridge Cognition

Alan Thomas

  • Nothing to Disclose

Giovanna Zamboni

  • Nothing to Disclose

Henrik Zetterberg

  • Nothing to Disclose